Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts

Baris Gencer, Tinh-Hai Collet, Vanessa Virgini, Douglas C Bauer, Jacobijn Gussekloo, Anne R Cappola, David Nanchen, Wendy P J den Elzen, Philippe Balmer, Robert N Luben, Massimo Iacoviello, Vincenzo Triggiani, Jacques Cornuz, Anne B Newman, Kay-Tee Khaw, J Wouter Jukema, Rudi G J Westendorp, Eric Vittinghoff, Drahomir Aujesky, Nicolas Rodondi, Thyroid Studies Collaboration, Baris Gencer, Tinh-Hai Collet, Vanessa Virgini, Douglas C Bauer, Jacobijn Gussekloo, Anne R Cappola, David Nanchen, Wendy P J den Elzen, Philippe Balmer, Robert N Luben, Massimo Iacoviello, Vincenzo Triggiani, Jacques Cornuz, Anne B Newman, Kay-Tee Khaw, J Wouter Jukema, Rudi G J Westendorp, Eric Vittinghoff, Drahomir Aujesky, Nicolas Rodondi, Thyroid Studies Collaboration

Abstract

Background: American College of Cardiology/American Heart Association guidelines for the diagnosis and management of heart failure recommend investigating exacerbating conditions such as thyroid dysfunction, but without specifying the impact of different thyroid-stimulation hormone (TSH) levels. Limited prospective data exist on the association between subclinical thyroid dysfunction and heart failure events.

Methods and results: We performed a pooled analysis of individual participant data using all available prospective cohorts with thyroid function tests and subsequent follow-up of heart failure events. Individual data on 25 390 participants with 216 248 person-years of follow-up were supplied from 6 prospective cohorts in the United States and Europe. Euthyroidism was defined as TSH of 0.45 to 4.49 mIU/L, subclinical hypothyroidism as TSH of 4.5 to 19.9 mIU/L, and subclinical hyperthyroidism as TSH <0.45 mIU/L, the last two with normal free thyroxine levels. Among 25 390 participants, 2068 (8.1%) had subclinical hypothyroidism and 648 (2.6%) had subclinical hyperthyroidism. In age- and sex-adjusted analyses, risks of heart failure events were increased with both higher and lower TSH levels (P for quadratic pattern <0.01); the hazard ratio was 1.01 (95% confidence interval, 0.81-1.26) for TSH of 4.5 to 6.9 mIU/L, 1.65 (95% confidence interval, 0.84-3.23) for TSH of 7.0 to 9.9 mIU/L, 1.86 (95% confidence interval, 1.27-2.72) for TSH of 10.0 to 19.9 mIU/L (P for trend <0.01) and 1.31 (95% confidence interval, 0.88-1.95) for TSH of 0.10 to 0.44 mIU/L and 1.94 (95% confidence interval, 1.01-3.72) for TSH <0.10 mIU/L (P for trend=0.047). Risks remained similar after adjustment for cardiovascular risk factors.

Conclusion: Risks of heart failure events were increased with both higher and lower TSH levels, particularly for TSH ≥10 and <0.10 mIU/L.

Conflict of interest statement

Conflict of Interest Disclosures: None.

Figures

Figure 1
Figure 1
Hazard Ratios for Heart Failure Events According to Thyroid-Stimulating Hormone Levels. Abbreviations: CI: Confidence Interval; HF: Heart Failure; HR: Hazard Ratio; TSH: Thyroid-Stimulating Hormone. Age- and gender-adjusted HRs and their 95% CI are represented by squares. Squares to the right of the solid lines indicate increased risk of HF events. Sized of data markers are proportional to the inverse of the variance of the HRs.

Source: PubMed

3
Subskrybuj